Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

Abstract SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrew D. Moura, Hernan H. M. da Costa, Victor A. Correa, Ana K. de S. Lima, José A. L. Lindoso, Elizabeth De Gaspari, Marisa A. Hong, Jair P. Cunha-Junior, Carlos R. Prudencio
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/baaf3e7ab920494cabc4ae3c7d35139c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:baaf3e7ab920494cabc4ae3c7d35139c
record_format	dspace
spelling	oai:doaj.org-article:baaf3e7ab920494cabc4ae3c7d35139c2021-12-02T17:51:31ZAssessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients10.1038/s41598-021-95045-z2045-2322https://doaj.org/article/baaf3e7ab920494cabc4ae3c7d35139c2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95045-zhttps://doaj.org/toc/2045-2322Abstract SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8–14 and 15–21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.Andrew D. MouraHernan H. M. da CostaVictor A. CorreaAna K. de S. LimaJosé A. L. LindosoElizabeth De GaspariMarisa A. HongJair P. Cunha-JuniorCarlos R. PrudencioNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andrew D. Moura Hernan H. M. da Costa Victor A. Correa Ana K. de S. Lima José A. L. Lindoso Elizabeth De Gaspari Marisa A. Hong Jair P. Cunha-Junior Carlos R. Prudencio Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
description	Abstract SARS-CoV-2 is considered a global emergency, resulting in an exacerbated crisis in the health public in the world. Although there are advances in vaccine development, it is still limited for many countries. On the other hand, an immunological response that mediates protective immunity or indicates that predict disease outcome in SARS-CoV-2 infection remains undefined. This work aimed to assess the antibody levels, avidity, and subclasses of IgG to RBD protein, in symptomatic patients with severe and mild forms of COVID-19 in Brazil using an adapted in-house RBD-IgG ELISA. The RBD IgG-ELISA showed 100% of specificity and 94.3% of sensibility on detecting antibodies in the sera of hospitalized patients. Patients who presented severe COVID-19 had higher anti-RBD IgG levels compared to patients with mild disease. Additionally, most patients analyzed displayed low antibody avidity, with 64.4% of the samples of patients who recovered from the disease and 84.6% of those who died in this avidity range. Our data also reveals an increase of IgG1 and IgG3 levels since the 8th day after symptoms onset, while IgG4 levels maintained less detectable during the study period. Surprisingly, patients who died during 8–14 and 15–21 days also showed higher anti-RBD IgG4 levels in comparison with the recovered (P < 0.05), suggesting that some life-threatening patients can elicit IgG4 to RBD antibody response in the first weeks of symptoms onset. Our findings constitute the effort to clarify IgG antibodies' kinetics, avidity, and subclasses against SARS-CoV-2 RBD in symptomatic patients with COVID-19 in Brazil, highlighting the importance of IgG antibody avidity in association with IgG4 detection as tool laboratory in the follow-up of hospitalized patients with more significant potential for life-threatening.
format	article
author	Andrew D. Moura Hernan H. M. da Costa Victor A. Correa Ana K. de S. Lima José A. L. Lindoso Elizabeth De Gaspari Marisa A. Hong Jair P. Cunha-Junior Carlos R. Prudencio
author_facet	Andrew D. Moura Hernan H. M. da Costa Victor A. Correa Ana K. de S. Lima José A. L. Lindoso Elizabeth De Gaspari Marisa A. Hong Jair P. Cunha-Junior Carlos R. Prudencio
author_sort	Andrew D. Moura
title	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
title_short	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
title_full	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
title_fullStr	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
title_full_unstemmed	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
title_sort	assessment of avidity related to igg subclasses in sars-cov-2 brazilian infected patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/baaf3e7ab920494cabc4ae3c7d35139c
work_keys_str_mv	AT andrewdmoura assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT hernanhmdacosta assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT victoracorrea assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT anakdeslima assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT joseallindoso assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT elizabethdegaspari assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT marisaahong assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT jairpcunhajunior assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients AT carlosrprudencio assessmentofavidityrelatedtoiggsubclassesinsarscov2brazilianinfectedpatients
_version_	1718379250274271232

Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients

Ejemplares similares